New dengue vaccine trial aims to unlock better protection
NCT ID NCT05691530
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This early-stage study tests a potential new dengue vaccine in 127 healthy adults aged 18 to 59. Researchers want to see if the vaccine is safe and how the immune system responds, especially in people who have been exposed to dengue before. Participants receive one shot and are closely monitored for side effects and immune changes over 7 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPONSE TO DENGUE EXPOSURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.